Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Nasdaq Turns Lower; Crude Oil Down Over 3%
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Friday. 
Via Benzinga
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares rose 58.1% to $2.45 in pre-market trading. PaxMedica entered into committed equity investment agreement for up to $20 million with Lincoln Park Capital. 
Via Benzinga
G1 Therapeutics: Q3 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
G1 Therapeutics Return On Capital Employed Insights
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
G1 Therapeutics Announces Pricing of Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
G1 Therapeutics Announces Proposed Public Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics: Q2 Earnings Insights
  G1 Therapeutics (NASDAQ:GTHX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
G1 Therapeutics: Q1 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. 
Via Benzinga
Analyst Ratings For G1 Therapeutics
Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
Via Benzinga
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - 
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
From G1 Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities
WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
G1 Therapeutics: Q4 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021
Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ: 
Via Benzinga
G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript
GTHX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.